Skip to main content

Clinical Watch: October 2018

Download PDF

In this issue of Clinical Watch, we discuss filgrastim and its biosimilars. We suggest criteria for the first oral treatment of Fabry disease and review a study evaluating the timing of opioid use disorder treatment in adolescents and young adults. Lastly, we review the utilization of ADHD stimulants across age groups.

For more information about our solutions, please visit conduent.com/pharmacysolutions.

Print